Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?

Abstract

BACKGROUND:To quantify the magnitude of benefit of the addition of hormone treatment (HT) to exclu-

Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer

“…This finding has resulted in decreased incidence and severity of rectal adverse events [3,4]. It has also been confirmed that combining HT with EBRT significantly improved not only biochemical control but also survival outcomes compared with EBRT alone [5,6]. These benefits were observed with both short-term (3-6 months) and long-term (>1 year) HT [5].…”

“…Meanwhile, the survival benefits of adding hormonal therapy (HT) to the standard doses of EBRT had also been confirmed [5,6]. The survival benefit of combining HT with EBRT over EBRT alone was observed in both…”

Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study

“…The EORTC trial 30891 randomised 985 patients with cT1-4, non-metastatic PCa patients unsuitable for curatively intended treatment and found an OS benefit of immediate castration compared to deferred therapy [20]. Finally, two meta-analyses of randomised trials have shown a PCa-specific and OS benefit of adding ADT to external beam radiotherapy with curative intent [21,22]. These studies advocate in favour early castration-based therapy in patients with locally advanced or lymph node positive PCa.…”

Tratamiento combinado con radioterapia externa y hormonoterapia en los pacientes con cáncer de próstata localmente avanzado: factores predictivos de toxicidad genitourinaria

“…Después de este estudio otros confirman sus resultados [9][10][11][12][13][14] , quedando constancia de la utilidad del tratamiento combinado. Widmark et al…”